Trials documents: the essentials

Clinical trials generate a significant volume of documentation. ICH-GCP E6(R2), specifically Section 8 of the guideline, defines "essential documents" as those which, individually and collectively, allow the conduct of the trial and the quality of the data to be evaluated. That framing matters: the list isn't there to create bureaucracy for its own sake. Each document is included because, without it, an inspector or auditor would have no way to independently confirm a specific part of the trial happened the way it was supposed to. Getting these right matters across all three phases of a trial: before it starts, while it runs, and after it closes.

Before the clinical phase

Documents at this stage establish that the trial is properly set up and that risks have been considered:

• Investigator's Brochure (IB)
• Signed protocol
• Sample CRF or eCRF
• Participant Information Sheet (PIS) and Informed Consent Form (ICF)
• Financial agreements and insurance documentation
• Signed agreements between all parties
• REC/IEC/IRB review and composition records
• Regulatory authority authorisation
• Normal value range lists for key assessments
• Accreditation documentation for relevant sites or laboratories
• Investigational product labels and handling instructions
• Shipping and receipt records
• Certificate of Analysis
• Decoding procedures for blinded trials
• Master randomisation list
• Pre-trial and initiation monitoring reports

These documents demonstrate that due diligence was done, that risks were considered, and that independent oversight was in place before any participant was enrolled.

During clinical conduct

Additional documentation is required while the trial is running:

• Investigator CVs (current)
• Monitoring visit reports
• Signed consent or eConsent forms for all participants
• Source documents and eSource data
• Completed and corrected CRF or eCRF forms
• Serious adverse event notifications and follow-ups
• Safety reports to regulators and ethics committees
• Interim and annual reports
• Participant screening, enrolment, and identification logs
• Investigational product accountability records
• Signature sheets for eCRF system access
• Records of retained biological samples where applicable

This documentation maintains transparency throughout, supports ongoing safety monitoring, and records all regulatory communications.

After completion or termination

Final documentation closes the loop:

• Records of investigational product disposal or destruction
• Completed participant identification lists
• Audit certificates
• Final close-out monitoring report
• Treatment allocation and unblinding documentation
• Final investigator reports to ethics committees and regulators
• Clinical Study Report

These demonstrate that the protocol was followed, that the product was handled and disposed of correctly, and that the study as a whole was conducted with the integrity required for regulatory review.

Why the three-phase structure matters

It's worth noticing that ICH E6(R2) organises essential documents by trial phase rather than by document type. That structure isn't incidental. It reflects the fact that a Trial Master File isn't really one document collection, it's three overlapping ones with different purposes: proving the trial was set up responsibly, proving it was conducted as approved, and proving it was closed out properly. A TMF that's strong in one phase and thin in another tends to produce exactly the kind of finding an inspector is trained to look for, because the gaps map directly onto a specific stage of the trial's lifecycle rather than being scattered randomly.

Questions to guide your document planning

The specific documents required depend on the nature of your study. Before finalising your TMF structure, consider:

• What is the intervention, and who is responsible for preparing it?
• How many sites are involved, and how are they distributed?
• How long will the study run?
• Will any data be collected remotely or via patient-reported outcomes?
• Which systems will store trial documents, and which will capture data?
• What are the roles of everyone involved, and who is ultimately accountable for each category of document?

Getting organised early tends to make everything else easier. And in a space where inspections and audits are a real possibility, a well-maintained Trial Master File, one that can demonstrate integrity at every one of the three phases above, is one of the most important things a study team can keep in order.

Digital TMF systems have made a lot of this more manageable than it used to be, with version control, automated timestamps, and completeness tracking built in rather than relying on someone manually checking a paper filing system against a checklist. But the underlying discipline hasn't changed. A digital system that isn't populated consistently across all three phases produces the exact same gaps a paper system would, just with a cleaner interface hiding them until someone goes looking.